Pancreatic Cancer Research

ResearcherJiangnan UniversityNo recent work listed

Hao Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3622-9897; OpenAlex author ID A5100721089. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2021: 2 papers · 2022: none · 2023: 3 papers

Papers 5

  1. The DEAD-box RNA helicase, DDX60, Suppresses immunotherapy and promotes malignant progression of pancreatic cancer. Last author DOI 10.1016/j.bbrep.2023.101488↗
  2. circPTPN22 attenuates immune microenvironment of pancreatic cancer via STAT3 acetylation. Co-author DOI 10.1038/s41417-021-00382-w↗
  3. miR-33a-3p regulates METTL3-mediated AREG stability and alters EMT to inhibit pancreatic cancer invasion and metastasis. Last author DOI 10.1038/s41598-023-39506-7↗
  4. ACTR3 promotes cell migration and invasion by inducing epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo-21-609↗
  5. NEAT1/miR-101-dependent Up-regulation of DNA-PKcs Enhances Malignant Behaviors of Pancreatic Ductal Adenocarcinoma Cells. Co-author DOI 10.7150/jca.58824↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tiantian Lai · 2 shared papers, 2023 · strength 0.36
  2. Xiaowen Su · 2 shared papers, 2023 · strength 0.36
  3. Shuo Zhang · 2 shared papers, 2021–2023 · strength 0.35
  4. Yuanlong Gu · 2 shared papers, 2021 · strength 0.32
  5. Leisheng Wang · 1 shared paper, 2023 · strength 0.19
  6. Yuan He · 1 shared paper, 2023 · strength 0.18
  7. Huiqing Zhang · 1 shared paper, 2023 · strength 0.18
  8. Chuang Chen · 1 shared paper, 2023 · strength 0.18
  9. Changhong Lian · 1 shared paper, 2023 · strength 0.18
  10. Shuo Zhang · 1 shared paper, 2023 · strength 0.17
  11. Junjing Zhou · 1 shared paper, 2023 · strength 0.17
  12. Yuzheng Xue · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.